Infusion Center Compliance: USP 797/800 + Medication Handling

Infusion centers operate under USP General Chapter 797 for sterile compounding and USP General Chapter 800 for hazardous drug handling, both enforced through state pharmacy boards, accreditation surveyors, and CMS Conditions of Participation at 42 CFR § 482.25 for hospital-based settings. Compliance turns on environmental monitoring, beyond-use dating, hazardous-drug containment, and documented staff competency.

What USP and state boards actually require for infusion centers

USP General Chapter 797, revised November 2023, classifies every compounded sterile preparation (CSP) into one of three categories with distinct facility, testing, and beyond-use date (BUD) requirements. Category 1 CSPs may be prepared in a segregated compounding area with a primary engineering control (PEC) but no full buffer room, BUD capped at 12 hours room temperature. Category 2 CSPs require an ISO Class 7 buffer room. Category 3 CSPs require additional sterility testing and extended BUDs. USP 797 is published by the United States Pharmacopeial Convention and becomes enforceable when adopted by a state pharmacy board, an accreditation body, or referenced under CMS Conditions of Participation.

USP General Chapter 800, in force since December 2019, applies to every entity that handles any drug on the NIOSH List of Hazardous Drugs — most chemotherapy agents, several biologics, and a number of non-oncology drugs (hormones, antivirals). The chapter requires a designated person, a written hazardous drug list, an Assessment of Risk for any drug the entity argues should be handled outside full 800 containment, engineering controls (containment primary engineering control, externally vented), PPE matched to the activity, medical surveillance, and spill-response procedures.

OSHA's Hazard Communication Standard at 29 CFR § 1910.1200 layers on top of USP 800 for hazardous drugs. Safety Data Sheets, container labeling, and worker training under HazCom apply independently. The 2024 OSHA update to the HazCom Standard added new label and SDS requirements; infusion centers handling hazardous drugs need their SDS library refreshed against the updated standard.

For hospital-based infusion centers, the CMS Conditions of Participation for Hospitals at 42 CFR § 482 — particularly § 482.25 Pharmaceutical services — bring USP standards into deemed-status surveys. Joint Commission Medication Management standards reference USP 797 and 800 directly. A finding under MM.05.01.07 (sterile compounding) is one of the more common medication-management citations in TJC surveys.

The documents you must maintain

What an infusion center actually has to produce when a state pharmacy board inspector or a Joint Commission surveyor arrives:

• Hazardous Drug List specific to the practice, reviewed at least every 12 months against the current NIOSH list
• Assessment of Risk for any hazardous drug the practice argues should be handled with less than full USP 800 containment (e.g., intact tablets in unit-of-use packaging)
• Designated Person document naming the qualified individual responsible for the hazardous drug program under USP 800
• Environmental monitoring records: viable air sampling, surface sampling, certification of primary engineering controls and secondary engineering controls on the cadence required by USP 797
• Competency assessments for every compounding person — initial, every 12 months thereafter for Category 1 and 2; every 6 months for Category 3 or higher-risk activities. Includes media-fill test results, gloved-fingertip and thumb sampling, surface cleaning and disinfection competency
• Beyond-use date calculations for every CSP type prepared, with the rationale tied to USP 797 Category and storage conditions
• PPE inventory and donning/doffing competency for hazardous drug handling personnel
• Spill kit inventory and spill-response drill log
• Medical surveillance records for hazardous-drug-exposed personnel where the practice has elected medical surveillance (USP 800 references but does not mandate; many states do)
• Master Formulation Record and Compounding Record for each CSP — required content listed in USP 797 General Considerations
• Cleaning and disinfection logs for the buffer area, anteroom, and primary engineering controls

The binder failure pattern: practices have the SOPs and have the equipment, but the competency-assessment log is missing the most recent media-fill date, or the gloved-fingertip sampling is more than 12 months old. Surveyors find that gap immediately.

How audits actually work in infusion settings

State pharmacy board inspections of infusion centers typically follow a structured worksheet. The inspector reviews the facility (engineering controls certification, smoke-pattern testing, environmental monitoring), then competency records, then a sample of CSPs prepared during a recent shift cross-referenced against the master formulation record and compounding record. For hazardous drugs, the inspector reviews the Hazardous Drug List, the Assessment of Risk for any exempted drug, PPE selection, and spill-response readiness.

What infusion centers most often miss is the USP 800 hazardous-drug list update that arrives mid-year. The NIOSH list is republished every 4 years with interim updates; a drug added in a 2024 update needs to be on the practice's list, in the Assessment of Risk, and in staff training before the next inspection. Inspectors check the date on the practice's hazardous drug policy against the most recent NIOSH publication.

Joint Commission surveyors take a different angle. Under deemed-status surveys, TJC uses the Medication Management chapter and traces medications from order through administration. The tracer methodology means a surveyor may pick a single chemotherapy administration and follow it back to the compounding record, the BUD calculation, the storage temperature log, and the staff competency for the person who compounded it. Any break in the chain is a finding.

CMS validation surveys following a TJC accreditation finding go deeper — particularly on environmental monitoring trends and corrective action documentation when monitoring exceeded action thresholds.

Common gaps unique to infusion practice

In USP 797/800 surveys we have responded to, the same gaps appear repeatedly:

• Stale gloved-fingertip and surface sampling — required at least every 6 months for category 2 and after every media-fill for compounding personnel. Practices schedule the initial sample at hire and miss the recurring cadence.
• Beyond-use date calculations that do not match the storage location — a Category 1 CSP labeled with a 24-hour BUD but stored at room temperature instead of refrigeration.
• Assessment of Risk that names hazardous drugs but does not justify why containment is reduced — the document must explain the rationale, not just list the drugs.
• Missing externally-vented hood for hazardous drug compounding — USP 800 requires negative-pressure containment with external venting; recirculating HEPA-only configurations do not meet the standard.
• Spill kits expired or incomplete — chemo spill kits expire; replacement after every use or after expiration is the rule.
• Training records that do not differentiate USP 797 from USP 800 — the two chapters require different competencies; a single "sterile compounding" training does not document USP 800 hazardous drug handling.
• No segregation of hazardous drug storage from non-hazardous storage — USP 800 requires separate, negative-pressure storage for hazardous drugs.

Maintenance cadence

The realistic minimum cadence for an infusion center binder:

• Daily: cleaning and disinfection log; PEC pre-use checks; temperature logs for refrigerated CSPs and hazardous drug storage
• Weekly: surface disinfection of buffer area and pass-through; spill kit inventory check
• Monthly: hazardous drug storage temperature/humidity verification; quality audit of CSPs prepared
• Every 6 months: gloved-fingertip and surface sampling for personnel; competency reassessment for Category 3 personnel; environmental monitoring (viable air sampling) reanalysis; PEC and SEC certification at intervals not exceeding 6 months, plus recertification after any relocation, alteration, or major service event (Joint Commission USP 797 sterile-compounding FAQ)
• Annually: full competency reassessment for Category 1 and 2 compounding personnel; USP 797 and 800 policy review; Hazardous Drug List update against the current NIOSH list; Assessment of Risk review
• On every personnel change: revoke access to compounding area, document offboarding, retrain replacement to documented competency before independent compounding

State preemption: where 797/800 enforcement actually differs

California — State Board of Pharmacy regulation 16 CCR § 1735 adopts USP 797 and 800 by reference with several California-specific provisions, including stricter Assessment of Risk documentation and required state-specific training for sterile compounding personnel. Health and Safety Code § 1226 governs ambulatory surgical clinic licensure; an infusion center co-located with surgical services may fall under that licensing regime additionally.

Texas — Texas State Board of Pharmacy 22 TAC § 291.133 (pharmacies compounding sterile preparations) is the operative sterile-compounding rule and references USP 797/800 for compounding standards, including the hazardous-drug provisions. Texas has been one of the more active inspection programs since the 2014 NECC tragedy and follows up complaint-driven inspections aggressively.

New York — New York State Education Department, Office of the Professions, regulates pharmacy practice under 8 NYCRR Part 63. Sterile compounding by non-pharmacist personnel is more restricted than in many other states. New York additionally enforces the I-STOP electronic prescribing rule for any controlled-substance components of an infusion regimen.

Florida — Florida Board of Pharmacy 64B16-28 adopts USP 797 with state-specific permit requirements for sterile compounding pharmacies. Outsourcing facilities under section 503B of the FD&C Act registered in Florida face additional state inspection. Florida's E-FORCSE PDMP applies to controlled-substance components.

Where the AAAHC, ACHC, and CMS standards converge

For accredited infusion centers, AAAHC (Accreditation Association for Ambulatory Health Care) and ACHC (Accreditation Commission for Health Care) standards both reference USP 797 and 800 as the operative standards. AAAHC's Infusion-Specific Standards and ACHC's PCAB sterile compounding standards both expect the binder content described above. CMS deemed-status accreditation routes through one of these bodies; CMS validation surveys cross-check accreditation findings.

How d3rx fits

The d3rx specialty compliance binder includes a USP 797/800 module that maintains the policies, competency log, environmental monitoring tracker, Hazardous Drug List, Assessment of Risk, and inspection-ready document index. It is a source-grounded administrative documentation aid. It does not certify compliance, provide legal advice, replace counsel, or guarantee an inspection outcome. The practice remains responsible for maintaining engineering controls, performing the environmental monitoring, and operating its compounding program. See compliance binder for the binder structure or audit defense for state pharmacy board response support.

D3rx compliance guides are administrative documentation aids. They do not certify compliance, provide legal advice, replace counsel, or guarantee an audit outcome. The practice remains responsible for reviewing, adopting, and maintaining its compliance program.